A Randomized, Multicenter Masked Comparison Trial of Poractant Alfa (Curosurf) versus Beractant (Survanta) in the Treatment of Respiratory Distress Syndrome in Preterm Infants

We compared the onset of clinical response and safety of two surfactants, poractant alfa (Curosurf, Chiesi Pharmaceuticals, Parma, Italy) and beractant (Survanta, Ross Laboratories, Columbus, OH), for treatment of respiratory distress syndrome (RDS) in preterm infants weighing 750 to 1750 g at birth and <35 weeks gestation. The study was performed as a 20-center prospective, randomized, masked comparison trial. Preterm infants (n = 293) with RDS were randomized to receive an initial dose of either 100 (n = 96) or 200 (n = 99) mg/kg of poractant alfa or 100 (n = 98) mg/kg of beractant. All repeat dosing was given at 100 mg/kg. The onset of clinical response after the first dose was studied by comparing changes in the fraction of inspired oxygen (FIO ₂) between 0 and 6 hours measured using the area under the curve (FIO ₂ AUC_0-6); other outcomes were assessed for the entire cohort at 28 days and for infants born at ≤ 32 weeks gestation at 36 weeks postconceptional age. We found that the mean FIO ₂ AUC_0-6 values for the 100 and 200 mg/kg poractant alfa groups were both significantly lower than the mean FIO ₂ AUC_0-6 values for the beractant group (p < 0.005) but were not different from each other. Other outcomes were not different among the three groups for the entire cohort, but in infants born at ≤ 32 weeks gestation, mortality up to 36 weeks postconceptional age was significantly less in the 200 mg/kg poractant alfa group than in either the beractant group (3% versus 11%; p = 0.034) or in the 100 mg/kg poractant alfa group (3% versus 11%; p = 0.046). Need for more than one dose of surfactant was significantly lower in infants treated with an initial dose of 200 mg/kg poractant alfa in comparison to the beractant-treated group (p < 0.002). Treatment with poractant alfa (200 mg/kg initial dose) resulted in rapid reduction in supplemental oxygen with fewer additional doses of surfactant versus treatment with beractant in infants <35 weeks gestation with RDS, and significantly reduced mortality (p <0.05) than either beractant or poractant alfa (100 mg/kg dosing) in infants ≤32 weeks gestation with RDS.

Respiratory distress syndrome - surfactant - mortality - preterm

REFERENCES

• 1 Couser R J, Ferrara T B, Ebert J, Hoekstra R E, Fangman J J. Effects of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease.  J Pediatr. 1990;  116 119-124
• 2 Mercier C E, Soll R F. Clinical trials of natural surfactant extract in respiratory distress syndrome.  Clin Perinatol. 1993;  20 711-735
• 3 Jobe A H. Pulmonary surfactant therapy.  N Engl J Med. 1993;  328 861-868
• 4 Vermont-Oxford Neonatal Network . A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome.  Pediatrics. 1996;  97 1-6
• 5 Horbar J D, Wright L L, Soll R F et al.. A multicenter, randomized trial comparing two surfactants for the treatment of neonatal respiratory distress syndrome. National Institute of Child Health and Human Development Neonatal Research Network.  J Pediatr. 1993;  123 757-766
• 6 Halliday H L. Natural vs. synthetic surfactants in neonatal respiratory distress syndrome.  Drugs. 1996;  51 226-237
• 7 Ainsworth S B, Beresford M W, Milligan D WA et al.. Pumactant and poractant alfa for treatment of respiratory distress syndrome in neonates born at 25-29 weeks' gestation: a randomised trial.  Lancet. 2000;  355 1387-1392
• 8 Soll R F, Blanco F. 2002 Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. (Cochrane Review). In: The Cochrane Library 4. Oxford, UK; Update Software Ltd.
• 9 Bloom B T, Kattwinkel J, Hall R T et al.. Comparison of Infasurf (calf lung surfactant extract) to Survanta (beractant) in the treatment and prevention of respiratory distress syndrome.  Pediatrics. 1997;  100 31-38
• 10 Speer C P, Gefeller O, Groneck P et al.. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome.  Arch Dis Child Fetal Neonatal Ed. 1995;  72 F8-F13
• 11 Baroutis G, Kaleyias J, Liarou T, Papathoma E, Hatzistamatiou Z, Costalos C. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome.  Eur J Pediatr. 2003;  162 476-480
• 12 Collaborative European Multicenter Study Group . Surfactant replacement therapy for severe neonatal respiratory distress syndrome: an international randomized clinical trial.  Pediatrics. 1988;  82 683-691
• 13 Egberts J, Brand R, Walti H, Bevilacqua G, Breart G, Gardini F. Mortality, severe respiratory distress syndrome, and chronic lung disease of the newborn are reduced more after prophylactic than after therapeutic administration of the surfactant Curosurf.  Pediatrics. 1997;  100 E4
• 14 Soll R F, Hoekstra R E, Fangman J J et al.. Multicenter trial of single-dose modified bovine surfactant extract (Survanta) for prevention of respiratory distress syndrome.  Pediatrics. 1990;  85 1092-1102
• 15 Hoekstra R E, Jackson J C, Myres T F et al.. Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome.  Pediatrics. 1991;  88 10-18
• 16 Robertson B, Curstedt T, Johansson J, Jornvall H, Kobayashi T. Structural and functional characterization of porcine surfactant isolated by liquid-gel chromatography. In: von Wichert P, Muller B Basic Research on Lung Surfactant. Progress in Respiration Research. Vol. 25. Basel; Karger 1990: 237-246
• 17 Vento M, Asensi M, Sastre J, Garcia-Sala F, Pallardo F V, Vina J. Resuscitation with room air instead of 100% oxygen prevents oxidative stress in moderately asphyxiated term neonates.  Pediatrics. 2001;  107 642-647
• 18 Rozycki H J, Comber P G, Huff T F. Cytokines and oxygen radicals after hyperoxia in preterm and term alveolar macrophages.  Am J Physiol Lung Cell Mol Physiol. 2002;  282 L1222-L1228
• 19 Bourbia A, Rozycki H. Activation of NF-κB from tracheal lavage fluid in ventilated premature infants is related to oxygen concentration.  Pediatr Res. 2002;  51 354A
• 20 Sebald M, Zhu N L, Li C, Ramanathan R, Minoo P. Repression of Bmp4 promotor by TNF-alpha in lung epithelial cells.  Pediatr Res. 2002;  51 353A
• 21 Halliday H L, Tarnow-Mordi W O, Corcoran J D, Patterson C C. Multicentre randomised trial comparing high and low dose surfactant regimens for the treatment of respiratory distress syndrome (the Curosurf 4 trial).  Arch Dis Child. 1993;  69 276-280
• 22 Curosurf package insert. Parma, Italy; Chiesi Farmaceutici, SpA
• 23 Bernhard W, Mottaghian J, Gebert A, Rau G A, Hardt H, Poets C F. Commercial versus native surfactants: surface activity, molecular components, and the effect of calcium.  Am J Respir Crit Care Med. 2000;  162 1524-1533
• 24 Mizuno K, Ikegami M, Chen C-M, Ueda T, Jobe A. Surfactant protein-B supplementation improves in vitro function of a modified natural surfactant.  Pediatr Res. 1995;  37 271-276
• 25 Kobayashi T, Tashiro K, Yamamoto K, Nitta S, Ohmura S, Suzuki Y. Effects of surfactant proteins SP-B and SP-C on dynamic and static mechanics of immature lungs.  J Appl Physiol. 1997;  83 1849-1856
• 26 Verder H, Albertsen P, Ebbesen F et al.. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation.  Pediatrics. 1999;  103 E24